| Drug Type Antibody fusion proteins | 
| Synonyms ES 502, ES-502 | 
| Target | 
| Action inhibitors | 
| Mechanism KRAS G12V inhibitors(GTPase KRas G12V inhibitors) | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | China  | 27 May 2024 | |
| Liver Cancer | Preclinical | China  | 27 May 2024 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | China  | 27 May 2024 | 






